Pioneering CAR T Therapy Transforms Cancer Care in India
In India, two cancer patients treated with CAR T therapy have survived three years in one of the longest follow-ups in South India. Narayana Health's success showcases the potential of CAR T therapy, now domestically produced, providing hope for those with treatment-resistant lymphoma.
- Country:
- India
In a groundbreaking moment for cancer treatment in India, two patients in Bengaluru have achieved three years of survival following Chimeric Antigen Receptor T-cell (CAR T) therapy. The therapy is known for its potential in treating relapsed follicular lymphoma, marking a significant achievement in South India.
Dr Sharat Damodar, Chairman of the Oncology Collegium at Narayana Health, highlighted the transformative effects of CAR T therapy in a recent press conference. He emphasized that these cases demonstrate the therapy's potential for patients who have exhausted all conventional treatment options.
With domestic production now making CAR T therapy accessible and affordable in India, and with approval by the Drug Controller General of India (DCGI), patients no longer need to travel abroad for such advanced cancer care.
(With inputs from agencies.)
Google News